CN104173354B - 可治疗癌症的药学组合物 - Google Patents
可治疗癌症的药学组合物 Download PDFInfo
- Publication number
- CN104173354B CN104173354B CN201310205265.0A CN201310205265A CN104173354B CN 104173354 B CN104173354 B CN 104173354B CN 201310205265 A CN201310205265 A CN 201310205265A CN 104173354 B CN104173354 B CN 104173354B
- Authority
- CN
- China
- Prior art keywords
- cancer
- pharmaceutical compositions
- composition
- cell
- triterpenoid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 60
- 201000011510 cancer Diseases 0.000 title claims abstract description 55
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 53
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 claims abstract description 43
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 31
- 201000005202 lung cancer Diseases 0.000 claims abstract description 27
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 27
- OTUZGGSAOMCYNC-AEGHVTTBSA-N Ganoderic acid Me Chemical compound CC1(C)[C@H](OC(C)=O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CC\C=C(/C)C(O)=O)C)C[C@H](OC(C)=O)[C@@]4(C)C3=CC[C@H]21 OTUZGGSAOMCYNC-AEGHVTTBSA-N 0.000 claims abstract description 13
- 201000001275 rectum cancer Diseases 0.000 claims abstract description 12
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 11
- OTUZGGSAOMCYNC-UHFFFAOYSA-N UNPD47180 Natural products CC1(C)C(OC(C)=O)CCC2(C)C3=CCC4(C)C(C(CCC=C(C)C(O)=O)C)CC(OC(C)=O)C4(C)C3=CCC21 OTUZGGSAOMCYNC-UHFFFAOYSA-N 0.000 claims abstract description 10
- 201000007270 liver cancer Diseases 0.000 claims abstract description 9
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 9
- FRRMMEJOPQSLSE-UHFFFAOYSA-N Ganoderic acid S Natural products CC1(C)C(O)CCC2(C)C3=CCC4(C)C(C(C(CC=C(C)C(O)=O)OC(C)=O)C)CCC4(C)C3=CCC21 FRRMMEJOPQSLSE-UHFFFAOYSA-N 0.000 claims abstract description 7
- AQUHIKXTCOSRFY-GOEVOFJGSA-N Ganoderic acid S Chemical compound CC1(C)C(=O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CC\C=C(\C)C(O)=O)C)CC[C@@]4(C)C3=CC[C@H]21 AQUHIKXTCOSRFY-GOEVOFJGSA-N 0.000 claims abstract description 7
- AQUHIKXTCOSRFY-UHFFFAOYSA-N tyromycic acid Natural products CC1(C)C(=O)CCC2(C)C3=CCC4(C)C(C(CCC=C(C)C(O)=O)C)CCC4(C)C3=CCC21 AQUHIKXTCOSRFY-UHFFFAOYSA-N 0.000 claims abstract description 7
- OCLVBEOPEKEKNM-CAXIOAJTSA-N Ganoderic Acid T Chemical compound CC1(C)[C@H](OC(C)=O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H]([C@H](C\C=C(/C)C(O)=O)OC(C)=O)C)C[C@H](OC(C)=O)[C@@]4(C)C3=CC[C@H]21 OCLVBEOPEKEKNM-CAXIOAJTSA-N 0.000 claims abstract description 6
- OCLVBEOPEKEKNM-UHFFFAOYSA-N ganoderic acid T Natural products CC1(C)C(OC(C)=O)CCC2(C)C3=CCC4(C)C(C(C(CC=C(C)C(O)=O)OC(C)=O)C)CC(OC(C)=O)C4(C)C3=CCC21 OCLVBEOPEKEKNM-UHFFFAOYSA-N 0.000 claims abstract description 6
- 208000032839 leukemia Diseases 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 43
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 19
- 229960002584 gefitinib Drugs 0.000 claims description 19
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 5
- 230000009471 action Effects 0.000 claims description 5
- 244000000231 Sesamum indicum Species 0.000 claims description 3
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 69
- 101710194177 Glutamate-methylamine ligase Proteins 0.000 abstract description 16
- -1 GAT) Chemical compound 0.000 abstract description 12
- RXLRLJSRXDHQCH-WXUPVFRZSA-N Ganoderic acid R Natural products O([C@H]([C@@H](C)[C@@H]1[C@]2(C)[C@](C)(C=3C([C@]4(C)[C@H](C(C)(C)[C@H](OC(=O)C)CC4)CC=3)=CC2)CC1)C/C=C(\C(=O)O)/C)C(=O)C RXLRLJSRXDHQCH-WXUPVFRZSA-N 0.000 abstract description 6
- RXLRLJSRXDHQCH-ASNKJFCVSA-N Ganoderic acid R Chemical compound CC1(C)[C@H](OC(C)=O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H]([C@H](C\C=C(/C)C(O)=O)OC(C)=O)C)CC[C@@]4(C)C3=CC[C@H]21 RXLRLJSRXDHQCH-ASNKJFCVSA-N 0.000 abstract description 6
- OTUZGGSAOMCYNC-CRTLAZRUSA-N (E,6R)-6-[(3S,5R,10S,13R,14R,15S,17R)-3,15-diacetyloxy-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylhept-2-enoic acid Chemical compound CC1(C)[C@@H](OC(C)=O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CC\C=C(/C)C(O)=O)C)C[C@H](OC(C)=O)[C@@]4(C)C3=CC[C@H]21 OTUZGGSAOMCYNC-CRTLAZRUSA-N 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 79
- 230000000694 effects Effects 0.000 description 36
- 238000000034 method Methods 0.000 description 27
- 150000001875 compounds Chemical class 0.000 description 25
- 238000011282 treatment Methods 0.000 description 20
- 240000008397 Ganoderma lucidum Species 0.000 description 16
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 150000003648 triterpenes Chemical class 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- 230000005907 cancer growth Effects 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 7
- 229960002411 imatinib Drugs 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 229940090044 injection Drugs 0.000 description 7
- 229930182735 Ganoderic acid Natural products 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- RDMQPKIDHAFXKA-JNORPAGFSA-N Ganoderic Acid Am1 Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)CC(C)C(O)=O)C)CC(=O)[C@]21C RDMQPKIDHAFXKA-JNORPAGFSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 230000010304 tumor cell viability Effects 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 201000005296 lung carcinoma Diseases 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 230000003405 preventing effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
- 102000013563 Acid Phosphatase Human genes 0.000 description 2
- 108010051457 Acid Phosphatase Proteins 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000009458 Carcinoma in Situ Diseases 0.000 description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- YTVGSCZIHGRVAV-IYAQLQCNSA-N Ganoderic Acid D Chemical compound C([C@@]12C)CC(=O)C(C)(C)[C@@H]1C[C@H](O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)CC(C)C(O)=O)C)CC(=O)[C@]21C YTVGSCZIHGRVAV-IYAQLQCNSA-N 0.000 description 2
- YCWGPALSXRBKTM-IGULHRHQSA-N Ganoderic Acid X Natural products C[C@H](CCC=C(C)C(=O)O)[C@H]1C[C@H](OC(=O)C)[C@@]2(C)C3=CC[C@H]4C(C)(C)[C@H](O)CC[C@]4(C)C3=CC[C@]12C YCWGPALSXRBKTM-IGULHRHQSA-N 0.000 description 2
- YCWGPALSXRBKTM-FKJOTFDOSA-N Ganoderic Acid X Chemical compound CC1(C)[C@@H](O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CC\C=C(/C)C(O)=O)C)C[C@H](OC(C)=O)[C@@]4(C)C3=CC[C@H]21 YCWGPALSXRBKTM-FKJOTFDOSA-N 0.000 description 2
- IEDDICKFTXIWIP-UHFFFAOYSA-N Ganoderic acid D Natural products CC(CC(=O)CCC1CC(=O)C2(C)C3=C(C(=O)CC12C)C4(C)CCC(=O)C(C)(C)C4CC3O)C(=O)O IEDDICKFTXIWIP-UHFFFAOYSA-N 0.000 description 2
- 241000222336 Ganoderma Species 0.000 description 2
- YCWGPALSXRBKTM-UHFFFAOYSA-N Ganodermic acid TN Natural products CC1(C)C(O)CCC2(C)C3=CCC4(C)C(C(CCC=C(C)C(O)=O)C)CC(OC(C)=O)C4(C)C3=CCC21 YCWGPALSXRBKTM-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 206010021703 Indifference Diseases 0.000 description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229940122803 Vinca alkaloid Drugs 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229960002448 dasatinib Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229960001346 nilotinib Drugs 0.000 description 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- YCXUCEXEMJPDRZ-QWPKPZHNSA-N (2r,6s)-6-[(3s,5r,10s,12s,13r,14r,17r)-12-acetyloxy-3-hydroxy-4,4,10,13,14-pentamethyl-7,11,15-trioxo-1,2,3,5,6,12,16,17-octahydrocyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC(=O)C1=C2C(=O)[C@@H](OC(C)=O)[C@]2(C)[C@@H]([C@H](CC(=O)C[C@@H](C)C(O)=O)C)CC(=O)[C@]21C YCXUCEXEMJPDRZ-QWPKPZHNSA-N 0.000 description 1
- LCIUOVOXWPIXOR-YUWDPXJWSA-N (6r)-6-[(7s,10s,12s,13r,14r,17r)-7,12-dihydroxy-4,4,10,13,14-pentamethyl-3,11,15-trioxo-1,2,5,6,7,12,16,17-octahydrocyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid Chemical compound C([C@@]12C)CC(=O)C(C)(C)C1C[C@H](O)C1=C2C(=O)[C@@H](O)[C@]2(C)[C@@H]([C@@H](CC(=O)CC(C)C(O)=O)C)CC(=O)[C@]21C LCIUOVOXWPIXOR-YUWDPXJWSA-N 0.000 description 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- AXPZIVKEZRHGAS-UHFFFAOYSA-N 3-benzyl-5-[(2-nitrophenoxy)methyl]oxolan-2-one Chemical compound [O-][N+](=O)C1=CC=CC=C1OCC1OC(=O)C(CC=2C=CC=CC=2)C1 AXPZIVKEZRHGAS-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229930182942 Ganoderal Natural products 0.000 description 1
- BSEYIQDDZBVTJY-UHFFFAOYSA-N Ganoderic acid A Natural products CC(CC(=O)CCC1CC(O)C2(C)C3=C(C(=O)CC12C)C4(C)CCC(=O)C(C)(C)C4CC3O)C(=O)O BSEYIQDDZBVTJY-UHFFFAOYSA-N 0.000 description 1
- MDZGCORLSWTNDB-DMSHPXPKSA-N Ganoderic acid H Natural products C[C@H](CC=O)CC(=O)C[C@@H](C)[C@H]1CC(=O)[C@@]2(C)C3=C(C(=O)[C@@H](OC(=O)C)[C@]12C)[C@@]4(C)CC[C@H](O)C(C)(C)[C@@H]4CC3=O MDZGCORLSWTNDB-DMSHPXPKSA-N 0.000 description 1
- LCIUOVOXWPIXOR-OFNACUEDSA-N Ganoderic acid M Natural products O=C(O)[C@@H](CC(=O)C[C@@H](C)[C@H]1[C@@]2(C)[C@@H](O)C(=O)C=3[C@]4(C)[C@@H](C(C)(C)C(=O)CC4)C[C@H](O)C=3[C@@]2(C)C(=O)C1)C LCIUOVOXWPIXOR-OFNACUEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 101000905241 Mus musculus Heart- and neural crest derivatives-expressed protein 1 Proteins 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical class [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005250 beta ray Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 229930188845 ganoderic aldehyde Natural products 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- RDRCCJPEJDWSRJ-UHFFFAOYSA-N pyridine;1h-pyrrole Chemical compound C=1C=CNC=1.C1=CC=NC=C1 RDRCCJPEJDWSRJ-UHFFFAOYSA-N 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000011091 sodium acetates Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010129 solution processing Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 229920006163 vinyl copolymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (5)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310205265.0A CN104173354B (zh) | 2013-05-28 | 2013-05-28 | 可治疗癌症的药学组合物 |
HK15103207.6A HK1202453A1 (zh) | 2013-05-28 | 2015-03-31 | 可治療癌症的藥學組合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310205265.0A CN104173354B (zh) | 2013-05-28 | 2013-05-28 | 可治疗癌症的药学组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104173354A CN104173354A (zh) | 2014-12-03 |
CN104173354B true CN104173354B (zh) | 2017-12-12 |
Family
ID=51954883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310205265.0A Expired - Fee Related CN104173354B (zh) | 2013-05-28 | 2013-05-28 | 可治疗癌症的药学组合物 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN104173354B (zh) |
HK (1) | HK1202453A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115463137B (zh) * | 2022-09-02 | 2024-01-26 | 浙江寿仙谷植物药研究院有限公司 | 一种新型pd-1/pd-l1小分子抑制剂及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1823787A (zh) * | 2005-12-29 | 2006-08-30 | 华东理工大学 | 灵芝酸在制备癌转移抑制剂中的应用 |
CN1823788A (zh) * | 2005-12-29 | 2006-08-30 | 华东理工大学 | 灵芝酸在癌症治疗中作为增敏增效剂和抑制剂的应用 |
CN101084905A (zh) * | 2005-06-01 | 2007-12-12 | 华东理工大学 | 灵芝酸Me在肿瘤生长或增殖抑制剂中的应用 |
WO2008068602A2 (en) * | 2006-12-08 | 2008-06-12 | Atehortua Garces Lucia | A method to generate fungal biomass from a culture of differentiated mycelium |
CN102127138A (zh) * | 2010-01-18 | 2011-07-20 | 勇健工业股份有限公司 | 由废弃的灵芝太空包中分离灵芝酸的方法 |
-
2013
- 2013-05-28 CN CN201310205265.0A patent/CN104173354B/zh not_active Expired - Fee Related
-
2015
- 2015-03-31 HK HK15103207.6A patent/HK1202453A1/zh not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101084905A (zh) * | 2005-06-01 | 2007-12-12 | 华东理工大学 | 灵芝酸Me在肿瘤生长或增殖抑制剂中的应用 |
CN1823787A (zh) * | 2005-12-29 | 2006-08-30 | 华东理工大学 | 灵芝酸在制备癌转移抑制剂中的应用 |
CN1823788A (zh) * | 2005-12-29 | 2006-08-30 | 华东理工大学 | 灵芝酸在癌症治疗中作为增敏增效剂和抑制剂的应用 |
WO2008068602A2 (en) * | 2006-12-08 | 2008-06-12 | Atehortua Garces Lucia | A method to generate fungal biomass from a culture of differentiated mycelium |
CN102127138A (zh) * | 2010-01-18 | 2011-07-20 | 勇健工业股份有限公司 | 由废弃的灵芝太空包中分离灵芝酸的方法 |
Non-Patent Citations (1)
Title |
---|
灵芝主要活性物质及其药理作用研究进展;吕超田等;《安徽农学通报》;20111231;第17卷(第1期);第50-51页 * |
Also Published As
Publication number | Publication date |
---|---|
HK1202453A1 (zh) | 2015-10-02 |
CN104173354A (zh) | 2014-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105769891B (zh) | 低极性稀有人参皂苷混合物及其用途 | |
CN105482129B (zh) | 抗癌萃取物及化合物 | |
CN103462896A (zh) | 诱导癌细胞凋亡的方法和应用 | |
CN109689078A (zh) | 葡萄提取物及与其有关的方法 | |
CN104906558B (zh) | 治疗宫颈癌的含有乌司他丁的药物组合物 | |
CN102731365A (zh) | 猴头菌抑制幽门螺杆菌的生物小分子及其在治疗消化道疾病中的应用 | |
US20130164382A1 (en) | Ejaculum of animals as medicinal material and uses thereof in medicaments for treatment of diseases such as tumors, depression, etc | |
WO2015152577A2 (ko) | 골 질환 예방 및 치료용 조성물 | |
CN104173354B (zh) | 可治疗癌症的药学组合物 | |
US11524021B2 (en) | Use of ginsenoside M1 for manufacturing medicament for treating oral cancer | |
CN111803484B (zh) | 奥替溴铵在制备抗肿瘤药物中的应用 | |
CN113181166B (zh) | 莪术烯醇在制备抗肺癌药物中的应用 | |
CN112957357B (zh) | 一种靶向klf4泛素化的小分子抑制剂及其应用 | |
CN115177620A (zh) | 西奥罗尼或其药学上可接受的盐在制备预防或治疗滤泡淋巴瘤的药物中的应用 | |
TWI469784B (zh) | 可治療癌症之藥學組合物 | |
CN107174577A (zh) | 一种含有egcg的凝胶剂及其制备方法 | |
CN109731019B (zh) | 一种具有化疗增效作用的组合物,包括组成、制备及应用 | |
NO20130284A1 (no) | Fremgangsmater og sammensetninger for behandling av cancermetastase | |
CN103054802A (zh) | 介入治疗肝癌的前阳离子/阳离子脂质体姜黄素制剂及其制备方法 | |
Khadagwanshi et al. | Effect of Phaseolus vulgaris on E. coli induced peritonitis and bacteraemia in mice | |
CN109876145A (zh) | 醋酸棉酚和化疗药的联合用药物 | |
CN110075131A (zh) | 寨卡病毒减毒株在治疗脑胶质瘤中的应用 | |
CN109481424A (zh) | 异甘草素、药物组合物及其在治疗糖尿病肾病中的应用 | |
CN103877126B (zh) | 瘤盖拟层孔菌的药用用途及治疗肿瘤的药物组合物 | |
WO2022143984A1 (zh) | 一种用于治疗癌症的药物组合物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1202453 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180105 Address after: The new Taiwan China Taiwan New Taipei City Sijhih District five road 1 No. 81 20 floor Patentee after: SANHUA BIOLOGICAL TECHNOLOGY Co.,Ltd. Address before: The new Taiwan China Taiwan New Taipei City Sijhih District five road 1 No. 81 20 floor Patentee before: DOUBLE CRANE BIOTECHNOLOGY CO.,LTD. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1202453 Country of ref document: HK |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171212 |